Targeting FGFR3-TACC3 Fusion Protein in Cancer (VIDEO)

Columbia University Irving Medical Center

Caption

Columbia researchers have discovered how a gene fusion found in 3 percent of glioblastoma tumors boosts mitochondrial activity, triggering cancer. They suggest that a dual-treatment approach, combining a drug that targets the gene fusion protein with a mitochondrial inhibitor, may be effective in slowing the cancer's progression.

Credit

Iavarone Lab, Columbia University Medical Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.